Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus OLMESARTAN MEDOXOMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus OLMESARTAN MEDOXOMIL.
FILSPARI vs OLMESARTAN MEDOXOMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to decreased peripheral vascular resistance and reduced blood pressure.
200 mg orally once daily, with or without food.
20 mg orally once daily, titrate as needed to 40 mg once daily; maximum 40 mg daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Terminal elimination half-life: 10-15 hours; reaches steady-state after 3-5 days; clinically allows once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Renal: 35-50% as unchanged drug; biliary/fecal: 50-65% via bile into feces, primarily as parent drug.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB